Specifically, our data suggest that BC patients would benefit from an upregulation of FAAH expression and/or activity in the cancer cells, but due to the current technical limitations of gene therapy, a more rational approach to bring FAAH upregulation closer to the clinic would be to identify unequivocal upstream regulators that increase its expression or activity. This evidence concerns the gene FAAH and cancer.